뒤로
Liminatus Pharma Inc(LIMN) 가격
LIMN 주가 차트
LIMN 수입
Liminatus Pharma Inc
$1.84
-10.24%
$-0.2
종가: Feb 06, 16:00:00 GMT-5
$1.57
-14.13%
$-0.26
애프터마켓: Feb 06, 20:00:00 GMT-5
주요 통계
이전 종가
$2.05
시가
$2.15
일일 범위
$1.57 - $2.63
52주 범위
$0.54 - $33.66
거래량
43.4M
평균 거래량
5.3M
EPS(TTM)
-0.20
배당수익률
--
시가총액
$42.7M
LIMN란 무엇인가요?
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.